It's ugly out there for biopharmaceutical stocks in the US with the Nasdaq Biotechnology Index (NBI) down 2.1% over the past month, which has had a chilling effect on initial public offerings for the industry. The Nasdaq closed up 0.36% for the week ending 9 August, but it ended the day in the red after a bout of after-hours bad news from multiple drug developers on 8 August.
Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks
Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.
More from Financing
More from Business
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.